Calliditas Therapeutics (CALT)
(Delayed Data from NSDQ)
$40.00 USD
-0.16 (-0.40%)
Updated Sep 20, 2024 03:53 PM ET
4-Sell of 5 4
D Value A Growth D Momentum C VGM
Price, Consensus and EPS Surprise
CALT 40.00 -0.16(-0.40%)
Will CALT be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CALT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CALT
Travere Gains 11% on Securing Full FDA Nod for Kidney Disease Drug
Xencor (XNCR) Moves 14.3% Higher: Will This Strength Last?
CALT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Novartis (NVS) Presents Positive Data on Rare Kidney Disease Drug
Travere (TVTX) Slumps 41% on Mixed Results From IgAN Drug Study
Calliditas Therapeutics AB Sponsored ADR (CALT) Surges 16.1%: Is This an Indication of Further Gains?
Other News for CALT
Calliditas Therapeutics to be delisted from Nasdaq Stockholm
Delisting of Calliditas Therapeutics AB (publ) from Nasdaq Stockholm
Notice of extraordinary meeting of Calliditas Therapeutics AB (publ)
Calliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei
Calliditas Therapeutics to apply for delisting of common shares, ADSs